Interval Intraocular Pressure in Intravitreal Injection Study

• Status: Completed
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective study of IOP in Intravitreal injections to evaluate:

1. IOP effect of intravitreal injection

2. IOP response to prophylactic beta blocker or Prostaglandin vs control (Hypromellose) over multiple time periods

3. IOP response in correlation to number of injections, IOL, type of anti VEGF, co morbidities

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Timolol; Travoprost

Criteria

Inclusion Criteria:

• AMD patients requiring multiple intravitreal injections (Eylea or Lucentis), not necessarily 3 month loading.

• Age >50

• Chinese patients with ability to read Chinese ICF

Exclusion Criteria:

1. Known glaucoma

2. Corneal disease e.g. corneal scarring or opacity preventing fundal view

3. On steroid or anti glaucoma eye drops

4. Prior vitrectomy or glaucoma surgery

5. Recent intraocular surgery i.e. cataracts surgery

6. Pseudophakic with anterior chamber IOL

7. History of ocular inflammatory disease e.g. uveitis

8. Previous laser iridotomy

9. Recent intravitreal injection of steroid

10. Inability for regular follow-up